Three grant-funded projects will study lung metastases due to triple-negative breast cancer. The first project will focus on the role of PI 3-kinases, a signal protein, in tumor metastasis. The second project will look at a subset of cancer cells with stem-cell-like properties and determine if non-cancerous cells may trigger their stemness and how. The third project will focus on stem-cell-like cancer cells that express high levels of MenalNV, an invasive variant of the protein Mena, which is linked to metastasis.
“Triple-negative breast cancer lacks the receptors that we can target when treating other types of breast cancer, which makes it a formidable challenge for patients and clinicians,” Jonathan Backer, MD, professor of biochemistry, the William S. Lasdon chair in pharmacology at New York City-based Albert Einstein College of Medicine, and the grant’s principal investigator, said in the release. “Our findings from this study should help us understand the interactions between tumor and non-cancerous cells at metastatic sites and suggest strategies for treating metastatic breast cancer and, possibly, metastases caused by other cancers.”
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
